Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Business Wire

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe
From Atamyo Therapeutics
Via Business Wire
Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers
From HighField Biopharmaceuticals
Via Business Wire
Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
From Natera, Inc.
Via Business Wire
Tickers NTRA
Stratasys Announces Board Authorization of $50 Million Share Repurchase Program
From Stratasys Ltd.
Via Business Wire
Tickers SSYS
Barclays Doubles Private Cloud Estate With HPE GreenLake Cloud
From Hewlett Packard Enterprise
Via Business Wire
Tickers HPE
ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA® (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
PHINIA Publishes Industry-Leading Guide to Global Emission Regulations
From PHINIA INC
Via Business Wire
Tickers PHIN
Omni Design Technologies Partners with Aura Intelligent Systems on Next Generation Radar
From Omni Design Technologies
Via Business Wire
The Estée Lauder Companies Inc. Recommends Stockholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation And Do Not Tender Shares
From The Estée Lauder Companies Inc.
Via Business Wire
Tickers EL
H.I.G. Realty Invests in Ziegert Group GmbH in Germany
From H.I.G. Capital
Via Business Wire
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
From Exact Sciences Corp.
Via Business Wire
Tickers EXAS
Dubai to Host Dubai Woodshow’s 21st Edition, from April 14th to 16th, 2025
From Dubai Woodshow
Via Business Wire
Juniper Research: Quantum Computing - Commercial Revenue to Near $10bn Globally by 2030
From Juniper Research
Via Business Wire
International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone
From Thales
Via Business Wire
e.l.f. SKIN Is Salvation to Skincare Shame in Satirical “Divine Skintervention” Campaign
From e.l.f. SKIN
Via Business Wire
Tickers ELF
Circle and Sony Block Solutions Labs to Enable USDC on Soneium to Empower a Creator Economy
From Circle
Via Business Wire
Masimo Shares Final Thoughts Ahead of September 19 Annual Meeting Where Everything is at Stake
From Masimo Corporation
Via Business Wire
Tickers MASI
Pilbara Aboriginal artists share cultural stories for the 19th Colours of our Country exhibition
From Rio Tinto
Via Business Wire
Tickers ASX:RIO
Stonepeak-backed MIDC Completes Combination with PhilTower
From Stonepeak
Via Business Wire
OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Tickers OFIX
SMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Super Micro Computer, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Tickers SMCI
Politan Comments on Masimo’s Latest Attempt to Block a Fair Shareholder Vote
From Politan Capital Management
Via Business Wire
Tickers MASI
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
Alcoa Announces Agreement to Sell its 25.1% Stake in Ma’aden Joint Venture to Ma’aden
From Alcoa
Via Business Wire
Tickers AA ASX:AAI
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024
From Scorpion Therapeutics, Inc.
Via Business Wire
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
From Daiichi Sankyo
Via Business Wire
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
Tickers GMAB
Exelixis Presents Final Overall Survival Results from Phase 3 CONTACT-02 Pivotal Study Evaluating Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Castration-Resistant Prostate Cancer at ESMO 2024
From Exelixis, Inc.
Via Business Wire
Tickers EXEL
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.